Effective treatment for COVID-19 remains elusive, though urgently needed in the current pandemic. Repurposing marketed therapies may be an effective strategy for finding therapies quickly and recently in vitro and clinical testing of such therapies against SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) has skyrocketed. However, not all marketed drugs showing in vitro efficacy may achieve therapeutic concentrations in humans and discernment of which drugs have favorable pharmacokinetic properties can save time and resources for future studies. Here we compile marketed therapies, including supplements, having direct anti-viral and/or immunomodulatory activity, with in vitro, in vivo, and/or clinical data against alpha and beta coronaviruses into tables, alongside their pharmacokinetic properties. We point to several drugs or supplements available for immediate repurposing because they have achievable blood concentrations in humans compared to their inhibitory concentrations against coronaviruses. This compilation may contribute to the implementation of rapid future studies by narrowing the vast number of marketed drugs reported for potential efficacy against SARS-CoV-2 on the basis of their pharmacokinetic properties, mechanism of action, and previously published coronavirus data.